Peptide and GLP-1 answers, sorted.
Plain-English answers on GLP-1s and peptides: what the trials and FDA labels actually say, whether it is approved, what it costs, and the syringe math, with every source linked.
- Free calculators
- Every source linked
- FDA status first
Reconstitution calculator
U-100 syringeLive calculator. Arithmetic only; your prescriber sets the dose.
- Sourced guides
- 78
- Drug and peptide profiles
- 23
- Free calculators
- 7
- Primary sources cited
- 556
Explore by topic
Six sections, and each page answers one question in full.
CalculatorsReconstitution, mg to units, and dosing charts. Syringe math only, no login.7 tools
GLP-1sTirzepatide, semaglutide, retatrutide: dosage schedules, side effects, cost and legitimate access.20 pages
Peptides A–ZOne profile per peptide with FDA status, evidence level and what trials actually used.37 pages
GoalsWhat the evidence says for muscle, skin, hair, sleep and the popular stacks.9 pages
LearnWhat peptides are, whether they are legal and safe, and how reconstitution works.8 pages
SkincarePeptide serums and copper peptides: what the cosmetic studies actually tested.4 pages
Most-searched peptides
FDA status first, then the evidence, then the dose tables.
- GLP-1sFDA approvedTirzepatideA once-weekly injectable GIP and GLP-1 receptor agonist made by Eli Lilly, sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, obstructive sleep apnea). Evidence: FDA label
- GLP-1sFDA approvedSemaglutideA GLP-1 receptor agonist made by Novo Nordisk, sold as Wegovy injection and tablets (weight management, heart-risk reduction, MASH) and as Ozempic and Rybelsus (type 2 diabetes). Evidence: FDA label
- GLP-1sInvestigationalRetatrutideAn investigational once-weekly injectable from Eli Lilly (code name LY3437943) that activates the GIP, GLP-1 and glucagon receptors, studied for obesity, type 2 diabetes, knee osteoarthritis pain and sleep apnea. Evidence: Phase 3 trials
- PeptidesNot FDA approvedBPC-157A synthetic 15-amino-acid fragment of a protein found in human gastric juice, studied for tissue healing in animals. Evidence: Early human studies
- PeptidesCompounded (Rx)SermorelinA synthetic 29-amino-acid fragment of human growth hormone-releasing hormone that prompts the pituitary to release growth hormone. Evidence: Early human studies
- PeptidesFDA approvedTesamorelinA synthetic analog of growth hormone-releasing factor (GHRH), injected under the skin once a day to raise the body's own growth hormone. Evidence: FDA label
- PeptidesNot FDA approvedKPVA three-amino-acid peptide (Lys-Pro-Val), the C-terminal end of alpha-melanocyte-stimulating hormone, studied for anti-inflammatory effects in cells and animals. Evidence: Animal studies only
- PeptidesNot FDA approvedGHK-CuA naturally occurring tripeptide (glycine, histidine, lysine) bound to a copper ion, used in skin-care products as copper tripeptide-1. Evidence: Early human studies
Most-asked questions
- 1Tirzepatide dosage chart: Zepbound and Mounjaro doses, step by stepThe label takes tirzepatide from 2.5 mg to as high as 15 mg weekly in 4-week steps.
- 2Zepbound side effects: how common they are, what helps, when to callNausea hits 25% to 29% of people on Zepbound, mostly during dose increases.
- 3Cheapest GLP-1 without insurance: cash prices by drug and doseThe cheapest GLP-1 without insurance starts at $149 a month, but that buys a starter dose.
- 4BPC-157 dosage: why no human dose exists and what studies actually usedThere is no established BPC-157 dose for people.
- 5Retatrutide side effects: how common they are and what the trials sawNausea, diarrhea and constipation lead the list.
- 6Bacteriostatic water: what it is, how long it lasts, who must avoid itSterile water with 0.9% benzyl alcohol, so one vial can be used for up to 28 days.
Approved, or not?
- OrforglipronFDA approved
- PT-141FDA approved
- SemaglutideFDA approved
- SS-31 (elamipretide)FDA approved
- TesamorelinFDA approved
- TirzepatideFDA approved
- NAD+Compounded (Rx)
Latest news
All news- PolicyHHS says it will not act against compounding of six peptides, with conditionsHHS will not act against 503A compounding of BPC-157, TB-500, MOTS-c, KPV, epitalon and semax under ten conditions. None is FDA-approved.
- SafetyNSW Health reports a sharp rise in emergency visits linked to unapproved peptides, mostly retatrutideNSW Health counted 1,180 emergency visits mentioning unapproved peptides from July 2025 to September 2026, mostly retatrutide. About 18% led to admission.
- PolicyFDA sends an interim policy on compounding certain peptides to White House reviewAn FDA notice on compounding certain peptides reached White House review on October 14, 2026. HHS issued it on October 28 as an enforcement policy.
Why trust PeptideSorted
Checked against sources
Every guide is checked line by line against its cited sources by our editorial team, and names its reviewer.
Sourced, inline
FDA labels, published trials and registries, numbered and linked on every page. No claim without a source.
Describe, never prescribe
Dose tables report what labels and trials used. Calculators do arithmetic. Your prescriber sets the dose.
Not a shop
No research-chemical sales, vendor rankings or coupon codes. FDA status is printed before anything else.
Read the editorial policy, how medical review works, and the corrections log.
Peptide news, sorted. Plus the printable dose chart.
Sorted, every Tuesday: the week's peptide and GLP-1 news in five minutes: FDA moves, new studies explained, and price changes. Subscribe and the one-page dose and injection-site chart arrives first.
- FDA and legal changes, with the notice linked
- Three new studies, each with its main limitation
- GLP-1 cash price moves